Andrew covers daily market movers, newsworthy cannabis stocks and other small-cap briefs. He previously worked as a fact-checker for both PolitiFact and Guideposts, covered higher education for the Columbia Missourian and interned at Rolling Stone Magazine. Andrew earned his Bachelor of Journalism from the University of Missouri in 2017.
Scott Gottlieb's departure from the FDA could delay approvals for CBD companies
The company said it will float more than 11 million common shares at a price of US$0.45 per share